Replicel Life Sciences Inc V.RP

Alternate Symbol(s): REPCF

Technology Scientific & Technical Instruments

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.

TSXV:RP - Post by User

Replicel Life Sciences Inc > End of August

<< Previous

Bullboard Posts

Next >>

Comment by Ingiboyon Aug 19, 2023 3:27pm

79 Views

Post# 35596444

RE:RE:RE:RE:End of August

RPINVESTOR1 good to see you are still aboard.

I re-read the posted article on Shiseido.
Yes this new COO and soon to be CEO next year Fujiwara wants to change the direction of the company and take a more consumer - centric approach. Obviously they need to bring new technology to the market place.

I may be dreaming but I still think some sort of a deal between Replicel and Shiseido will be struck which will be very lucrative for the long suffering Replicel share holders.

<< Previous

Bullboard Posts

Next >>

Two micro-cap stocks with strong fundamentals